FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes

Dapagliflozin (Farxiga, AstraZeneca) has additionally been approved in the US for reducing hospitalization for heart failure (HF) in adults with type 2 diabetes and other cardiovascular risk factors.FDA Approvals

Source: Medscape Cardiology Headlines - October 21, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news